Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Active Biotech's collaboration partner MediGene has achieved positive results from a clinical Phase IIa trial of drug candidate RhuDex for the treatment of rheumatoid arthritis.
Subscribe to our email newsletter
In addition to positive safety data and the good adsorption after oral administration, a first indication of biological activity of RhuDex was observed. The data obtained in the trial regarding pharmacokinetics and bioavailability will, among other aspects, form the basis of the design of a comprehensive Phase II trial of RhuDex which is scheduled for 2009.
In parallel, a new pharmaceutical form of RhuDex has been developed and this new tablet form will provide additional treatment facilitation for the patients.
In the planned Phase II trial with the new formulation of RhuDex as a tablet, the patients will be treated during three months, and efficacy data for RhuDex are to be collected.